Victoria Delicado-Useros, Esther Navarro-Rodenas, Indalecio-M Sánchez-Onrubia, Carmen Ortega-Martínez, Antonia Alfaro-Espín, J. Pérez-Serra, F. García-Alcaraz, Julia Lozano-Serra, Lorena Robles-Fonseca, Teresa Pérez-Domenech
{"title":"Evolution of Acquired Humoral Immunity after Full Vaccination against SARS-CoV-2. IgG Levels in Healthcare Workers at 6 and 9 Months","authors":"Victoria Delicado-Useros, Esther Navarro-Rodenas, Indalecio-M Sánchez-Onrubia, Carmen Ortega-Martínez, Antonia Alfaro-Espín, J. Pérez-Serra, F. García-Alcaraz, Julia Lozano-Serra, Lorena Robles-Fonseca, Teresa Pérez-Domenech","doi":"10.21203/rs.3.rs-2093702/v1","DOIUrl":null,"url":null,"abstract":"Background: The COVID-19 pandemic continues to be a major worldwide health problem. The present study aims to contribute to surveillance of the immune and clinical response of vaccines to SARS-CoV-2. Methods Observational study of medication on acquired immunity and effectiveness of vaccines. Population: 620 workers in the health service of Almansa (Spain). Representative sample of 150 individuals. Sociodemographic, clinical, and epidemiological data and samples were recorded to determine anti- SARS-CoV2 serum IgG levels 6 and 9 months after vaccination with Pfizer. Results Mean age 46.45 years;76% women;85.1% working in a hospital. 19.3% had had COVID-19 in the year prior to vaccination. 96.7% were fully vaccinated with Pfizer/BioNTech. At 6 months, 100% seropositivity and mean IgG levels of 3017.2 AU/ml. Significant variations in IgG levels in individuals with prior COVID-19 infection and smokers. At 9 months, 99.3% remained seropositive;2.8% infected after vaccination. The repeated measures analysis showed a difference in means of 669.0 AU/ml (significant decrease in IgG levels of 28.9%). Conclusion Antibody levels remained positive 6 and 9 months after vaccination, although IgG levels were found to decay.","PeriodicalId":57190,"journal":{"name":"疫苗(英文)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"疫苗(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21203/rs.3.rs-2093702/v1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: The COVID-19 pandemic continues to be a major worldwide health problem. The present study aims to contribute to surveillance of the immune and clinical response of vaccines to SARS-CoV-2. Methods Observational study of medication on acquired immunity and effectiveness of vaccines. Population: 620 workers in the health service of Almansa (Spain). Representative sample of 150 individuals. Sociodemographic, clinical, and epidemiological data and samples were recorded to determine anti- SARS-CoV2 serum IgG levels 6 and 9 months after vaccination with Pfizer. Results Mean age 46.45 years;76% women;85.1% working in a hospital. 19.3% had had COVID-19 in the year prior to vaccination. 96.7% were fully vaccinated with Pfizer/BioNTech. At 6 months, 100% seropositivity and mean IgG levels of 3017.2 AU/ml. Significant variations in IgG levels in individuals with prior COVID-19 infection and smokers. At 9 months, 99.3% remained seropositive;2.8% infected after vaccination. The repeated measures analysis showed a difference in means of 669.0 AU/ml (significant decrease in IgG levels of 28.9%). Conclusion Antibody levels remained positive 6 and 9 months after vaccination, although IgG levels were found to decay.